Nicotinamide Riboside and Mitochondrial Metabolism

Exclusion Criteria

• •1. Unstable medical conditions as determined by the principal investigator
• •2. Clinically significant abnormal lab results at screening (e.g. AST and/or ALT \> 2 x ULN, and/or bilirubin \> 2 x ULN)
• •3. Subjects who have a planned surgery during the course of the trial
• •4. History of or a current diagnosis of any cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening). Subjects with cancer in full remission more than 5 years after diagnosis are acceptable.
• •5. History of blood/bleeding disorders
• •6. Immunocompromised individuals such as subjects that had undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
• •7. Hepatitis
• •8. Blood donation in the previous 2 months
• •9. Anemia (hemoglobin \<120)
• •10. Participation in a clinical research trial within 30 days prior to randomization
• •11. Allergy or sensitivity to study supplement ingredients
• •12. Individuals who are cognitively impaired and/or who are unable to give informed consent.
• •13. Any other condition, which in the principal investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may have posed significant risk to the subject.